BR9712278A - Processos e composições para imunomodulação - Google Patents

Processos e composições para imunomodulação

Info

Publication number
BR9712278A
BR9712278A BR9712278-5A BR9712278A BR9712278A BR 9712278 A BR9712278 A BR 9712278A BR 9712278 A BR9712278 A BR 9712278A BR 9712278 A BR9712278 A BR 9712278A
Authority
BR
Brazil
Prior art keywords
immunomodulation
compositions
processes
vivo
immunosuppression
Prior art date
Application number
BR9712278-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Alejandro A Aruffo
N Jan Chalupny
Lieping Chen
Robert S Mittler
Walter W Shuford
Anthony W Siadak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9712278A publication Critical patent/BR9712278A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9712278-5A 1996-10-11 1997-10-03 Processos e composições para imunomodulação BR9712278A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2827096P 1996-10-11 1996-10-11
PCT/US1997/018035 WO1998016249A1 (en) 1996-10-11 1997-10-03 Methods and compositions for immunomodulation

Publications (1)

Publication Number Publication Date
BR9712278A true BR9712278A (pt) 1999-08-31

Family

ID=21842492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712278-5A BR9712278A (pt) 1996-10-11 1997-10-03 Processos e composições para imunomodulação

Country Status (15)

Country Link
US (1) US6210669B1 (forum.php)
EP (1) EP0948353A1 (forum.php)
JP (1) JP2001502325A (forum.php)
KR (1) KR100520339B1 (forum.php)
CN (1) CN1232402A (forum.php)
AU (1) AU738981B2 (forum.php)
BR (1) BR9712278A (forum.php)
CA (1) CA2268340A1 (forum.php)
HU (1) HUP9904697A3 (forum.php)
IL (1) IL129138A0 (forum.php)
NO (1) NO991676D0 (forum.php)
NZ (1) NZ334691A (forum.php)
PL (1) PL188749B1 (forum.php)
RU (1) RU2192281C2 (forum.php)
WO (1) WO1998016249A1 (forum.php)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
KR100468321B1 (ko) * 2001-02-08 2005-01-27 학교법인 울산공업학원 종양 및 에이즈치료용 폴리펩타이드
US7651686B2 (en) * 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
KR100452954B1 (ko) * 2002-02-26 2004-10-14 주식회사 엘지생명과학 가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ES2422193T3 (es) * 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004006853A2 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
EP1575672A2 (en) * 2002-12-16 2005-09-21 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
WO2006029220A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Combination therapy with anti-ctla4 and anti-4-1bb antibodies
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
CA2589839C (en) * 2004-12-02 2016-04-05 Unilever N.V. Method for affinity purification
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
ES2642787T3 (es) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2010132389A2 (en) * 2009-05-14 2010-11-18 University Of Maryland, Baltimore Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
CA3019531A1 (en) * 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US20140234320A1 (en) * 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
RU2493873C1 (ru) * 2012-06-07 2013-09-27 Сергей Михайлович Юдин Инъекционный препарат для повышения спермопродукции у производителей сельскохозяйственных животных и петухов и способ его применения
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
US20150118222A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CN106999574B (zh) 2014-10-10 2022-05-24 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
PE20180394A1 (es) 2015-04-17 2018-02-28 Bristol Myers Squibb Co Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP4302782A3 (en) 2016-03-15 2024-03-27 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11400155B2 (en) 2016-05-20 2022-08-02 Biohaven Therapeutics Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
IL263744B2 (en) 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN110234319B (zh) 2016-11-23 2022-09-27 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
BR112019014991A2 (pt) 2017-01-20 2020-04-07 Magenta Therapeutics Inc composições e métodos para a supressão de células cd137+
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
MA50056A (fr) 2017-03-31 2020-02-05 Bristol Myers Squibb Co Procédés de traitement de tumeur
CN110546166B (zh) 2017-04-13 2024-03-29 艾吉纳斯公司 抗cd137抗体和其使用方法
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019100023A1 (en) 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
JP2021510533A (ja) * 2018-01-22 2021-04-30 江蘇恒瑞医薬股▲ふん▼有限公司 抗４−１ｂｂ抗体、その抗原結合フラグメント、およびその医学的使用
WO2019160829A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
US12037406B2 (en) 2018-03-23 2024-07-16 Eli Lilly And Company Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
SG11202008767XA (en) 2018-03-23 2020-10-29 Bristol Myers Squibb Co Antibodies against mica and/or micb and uses thereof
EA202092319A1 (ru) 2018-03-29 2021-03-04 Айовэнс Байотерапьютикс, Инк. Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
MX2020011134A (es) 2018-04-27 2020-11-11 Iovance Biotherapeutics Inc Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
CA3112599A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
MX2021003554A (es) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Proteinas de union a dll3 y metodos de uso.
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2022512915A (ja) 2018-11-05 2022-02-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
EP3876957B1 (en) 2018-11-05 2025-01-22 Iovance Biotherapeutics, Inc. Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
BR112021008573A2 (pt) 2018-11-05 2021-10-26 Iovance Biotherapeutics, Inc. Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor, para tratar um sujeito com câncer e de expansão de células t, população terapêutica de linfócitos infiltrantes de tumor, composição de linfócitos infiltrantes de tumor, saco de infusão estéril, preparação criopreservada, e, uso da composição de linfócitos infiltrantes de tumor.
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
US20230220341A1 (en) 2019-12-11 2023-07-13 lovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
BR112022016490A2 (pt) 2020-02-27 2022-10-11 Myst Therapeutics Llc Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
WO2021226061A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
JP2024503265A (ja) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物およびその使用の方法
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
JP2024509184A (ja) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍保存及び細胞培養組成物
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
EP4423755A2 (en) 2021-10-27 2024-09-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
MX9306682A (es) 1992-10-30 1994-04-29 Bristol Myers Squibb Co Ligandos del receptor de la matriz extracelular, que modulan la funcion de los leucocitos.
EP0719329B1 (en) * 1993-09-16 2010-01-06 Indiana University Research and Technology Corporation Human receptor h4-1bb
WO1996029348A1 (en) * 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
KR960035080U (ko) * 1995-04-25 1996-11-21 보일러용 연소 버너
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette

Also Published As

Publication number Publication date
KR20000049045A (ko) 2000-07-25
EP0948353A1 (en) 1999-10-13
HUP9904697A2 (hu) 2000-08-28
RU2192281C2 (ru) 2002-11-10
NO991676L (no) 1999-04-09
PL188749B1 (pl) 2005-04-29
AU4747097A (en) 1998-05-11
CN1232402A (zh) 1999-10-20
EP0948353A4 (forum.php) 1999-10-13
NZ334691A (en) 2000-12-22
IL129138A0 (en) 2000-02-17
WO1998016249A1 (en) 1998-04-23
KR100520339B1 (ko) 2005-10-12
CA2268340A1 (en) 1998-04-23
PL332699A1 (en) 1999-09-27
US6210669B1 (en) 2001-04-03
JP2001502325A (ja) 2001-02-20
AU738981B2 (en) 2001-10-04
NO991676D0 (no) 1999-04-09
HUP9904697A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
BR9712278A (pt) Processos e composições para imunomodulação
GR3024489T3 (forum.php)
MY154009A (en) Anti-alpha v beta 6 antibodies
EP0724651A4 (en) SYNTHETIC HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST AND NEUTRALIZING THE IMMUNODEFICIENCY VIRUS
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
ES2191702T3 (es) Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
WO2000052054A3 (en) ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF CANCER
IL128003A (en) MULTISPECIFIC BINDING MOLECULES COMPRISING A BINDING DETERMINANT WHICH BINDS AN FCalpha RECEPTOR
TR200002405T2 (tr) İnsan CD40' a karşı antikorlar
GB2301366A (en) Antibodies against E-selectin
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
ES520340A0 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas.
ATE404667T1 (de) Chromatin-regulatorgene
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
EP0688365A4 (en) REGULATING FERTILITY USING THE TRANSFORMING BETA GROWTH FACTOR
DE69522689D1 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
MXPA03011306A (es) Metodos para la preparacion y uso de 1a,24 (s) - hidroxivitamina d2.
TR200001265T2 (tr) Vasp' a karşı antikorlar, bunların hazırlanması için hibridoma hücreleri.
ES2109103T3 (es) Procedimiento para la preparacion de trialquilsilil-7 bacatina iii.
BR9305557A (pt) Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
BG101116A (en) Pyridylbisphosphonates and their use as therapeutical means

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]